Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Mar;11(3):649-651.
doi: 10.21037/jtd.2019.02.65.

It's far better to be alone than to be in bad company

Michael Duruisseaux  1   2 , Jacques Cadranel  3
Affiliations
Editorial

It's far better to be alone than to be in bad company

Michael Duruisseaux et al. J Thorac Dis. 2019 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: M Duruisseaux has received research funding from Novartis and Pfizer for institutional research program outside of the submitted paper. He has served as a consultant (advisory board) and received fees from Astra Zeneca, Boerhinger Ingelheim, Lilly, Novartis, Pfizer, Roche, Abbvie, MSD, BMS and Takeda. J Cadranel has received research funding for his institution from Astra Zeneca, Boerhinger Ingelheim, Novartis and Pfizer outside of the submitted paper. He has served as a consultant (advisory board) and received fees from Astra Zeneca, BMS, Boerhinger Ingelheim, Lilly, MSD, Novartis, Pfizer, Roche and Takeda.

Comment on

References

    1. Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016;387:1415-26. 10.1016/S0140-6736(16)00004-0 - DOI - PubMed
    1. Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012;104:228-39. 10.1093/jnci/djr523 - DOI - PMC - PubMed
    1. Dumenil C, Vieira T, Rouleau E, et al. Is there a specific phenotype associated with the different subtypes of KRAS mutations in patients with advanced non-small-cell lung cancers? Lung Cancer 2015;90:561-7. 10.1016/j.lungcan.2015.10.012 - DOI - PubMed
    1. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv192-iv237. 10.1093/annonc/mdy275 - DOI - PubMed
    1. Duruisseaux M, Besse B, Cadranel J, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget 2017;8:21903-17. 10.18632/oncotarget.15746 - DOI - PMC - PubMed